Item 5.02. Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
On December 16, 2020, the Board of Directors of Vaxcyte, Inc. (the "Company")
promoted Andrew Guggenhime, the Company's Chief Financial Officer and Chief
Business Officer, to President and Chief Financial Officer, effective January 1,
2021 (the "Effective Date"). Following the Effective Date, Grant Pickering, the
Company's President and Chief Executive Officer, will continue to serve as the
Company's Chief Executive Officer.
Mr. Guggenhime, age 52, has served as the Company's Chief Financial Officer and
Chief Business Officer since May 2020. From April 2014 to May 2020,
Mr. Guggenhime served as Chief Financial Officer at Dermira, Inc., a
biopharmaceutical company, until its acquisition by Eli Lilly and Company, and
from April 2014 to May 2018, he also served as Chief Operating Officer at
Dermira. From September 2011 to April 2014, Mr. Guggenhime served as Chief
Financial Officer of CardioDx, Inc., a molecular diagnostics life sciences
company, and as a member of the CardioDx board of directors from April 2014
until July 2016. Prior to that, Mr. Guggenhime served as Chief Financial Officer
at Calistoga Pharmaceuticals, Inc., a biotechnology company that was acquired by
Gilead Sciences, Inc. Mr. Guggenhime also previously served as Senior Vice
President and Chief Financial Officer at Facet Biotech Corporation, a
biotechnology company, Chief Financial Officer at PDL BioPharma, Inc. a
biotechnology company, and Vice President, Corporate Development and then Senior
Vice President and Chief Financial Officer at Neoforma, Inc., a provider of
supply-chain management solutions for the healthcare industry. Mr. Guggenhime
currently serves on the board of directors of Metacrine, Inc., a biotechnology
company. Mr. Guggenhime holds a B.A. in International Politics and Economics
from Middlebury College and an M.B.A. from the J.L. Kellogg Graduate School of
Management at Northwestern University.
Mr. Guggenhime has no family relationships with any director, executive officer
or person nominated or chosen by the Company to become a director or executive
officer of the Company. Mr. Guggenhime is not a party to any transaction
required to be disclosed pursuant to Item 404(a) of Regulation S-K.
1
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses
VAXCYTE, INC. 
